Ductal neoplasia of the pancreas: nosologic, clinicopathologic, and biologic aspects
- PMID: 16183479
- DOI: 10.1016/j.semradonc.2005.04.001
Ductal neoplasia of the pancreas: nosologic, clinicopathologic, and biologic aspects
Abstract
Most pancreatic neoplasia are of ductal lineage, characterized by tubule (gland), cyst, papilla, or mucin formation and expression of mucin-related glycoproteins and oncoproteins (eg, MUC1, CA19-9, CEA, DUPAN), as well as some subsets of cytokeratin (eg, CK19). Mutations of k-ras oncogene and DPC4 are also common in ductal neoplasia and generally not seen in nonductal tumors. A variety of pancreatic neoplasia fall under the heading of ductal neoplasia. Invasive ductal adenocarcinoma (DA) is the most important and constitutes the vast majority (>85%) of pancreatic tumors. DA is characterized by insidious infiltration and rapid dissemination, despite its relatively well-differentiated histologic appearance. In some variants of DA such as undifferentiated or sarcomatoid, evidence of ductal differentiation may be lacking or only focal. The presumed precursors of DA are microscopic intraductal proliferative changes that are now termed pancreatic intraepithelial neoplasia (PanIN). PanINs comprise a neoplastic transformation ranging from early mucinous change (PanIN-1A) to frank CIS (PanIN-3). A similar (in situ) neoplastic spectrum also characterizes intraductal papillary mucinous neoplasms and mucinous cystic neoplasms, which are cystic ductal-mucinous tumors with varying degrees of papilla formation, and may be associated with invasive carcinoma. As such, these can be regarded as mass-forming preinvasive neoplasia. Some intraductal papillary mucinous neoplasms are associated with invasive carcinoma of the colloid type. Colloid carcinoma of the pancreas appears to be a clinicopathologically distinct tumor with indolent behavior. Whereas most ductal pancreatic neoplasia are characterized by some degree of mucin formation, serous tumors, of which serous (microcystic) adenoma is the sole example, lack mucin formation, presumably because they recapitulate centroacinar ducts. They are typically benign tumors. It is recognized now that pancreatic carcinoma, like other malignant processes, is a genetic disease produced by progressive mutations in cancer-related genes. These alterations can be categorized as "early" such as k-ras mutation, HER-2/neu, PSCA, MUC5, and fascin overexpression; "intermediate" such as p16 inactivation, MUC1, and cyclin D1 overexpression; and finally as "late" such as p53 and DPC4 inactivation, BRCA2 mutation, and overexpression of ki-67, 14-3-3sigma, and mesothelin. Ductal neoplasia is the most important category among pancreatic tumors. It is important to appreciate the different types of ductal tumors because they vary greatly in their clinicopathologic characteristics and prognosis. Understanding the molecular mechanisms of ductal carcinogenesis will help develop more efficient prevention and therapy of these tumors.
Similar articles
-
The dichotomy in the preinvasive neoplasia to invasive carcinoma sequence in the pancreas: differential expression of MUC1 and MUC2 supports the existence of two separate pathways of carcinogenesis.Mod Pathol. 2002 Oct;15(10):1087-95. doi: 10.1097/01.MP.0000028647.98725.8B. Mod Pathol. 2002. PMID: 12379756
-
Where and when does pancreatic carcinoma start?Med Klin (Munich). 2004 Apr 15;99(4):191-5. doi: 10.1007/s00063-004-1028-3. Med Klin (Munich). 2004. PMID: 15085289
-
Overexpression of p21(WAF1/CIP1) is an early event in the development of pancreatic intraepithelial neoplasia.Cancer Res. 2001 Dec 15;61(24):8830-7. Cancer Res. 2001. PMID: 11751405
-
Current understanding of precursors to pancreatic cancer.J Hepatobiliary Pancreat Surg. 2007;14(3):217-23. doi: 10.1007/s00534-006-1165-6. Epub 2007 May 29. J Hepatobiliary Pancreat Surg. 2007. PMID: 17520195 Review.
-
Pancreatic tumors with cystic dilatation of the ducts: intraductal papillary mucinous neoplasms and intraductal oncocytic papillary neoplasms.Semin Diagn Pathol. 2000 Feb;17(1):16-30. Semin Diagn Pathol. 2000. PMID: 10721804 Review.
Cited by
-
Genetic Signature of Human Pancreatic Cancer and Personalized Targeting.Cells. 2024 Mar 29;13(7):602. doi: 10.3390/cells13070602. Cells. 2024. PMID: 38607041 Free PMC article. Review.
-
LncRNAs as nodes for the cross-talk between autophagy and Wnt signaling in pancreatic cancer drug resistance.Int J Biol Sci. 2024 Apr 29;20(7):2698-2726. doi: 10.7150/ijbs.91832. eCollection 2024. Int J Biol Sci. 2024. PMID: 38725864 Free PMC article. Review.
-
Purified human pancreatic duct cell culture conditions defined by serum-free high-content growth factor screening.PLoS One. 2012;7(3):e33999. doi: 10.1371/journal.pone.0033999. Epub 2012 Mar 19. PLoS One. 2012. PMID: 22442738 Free PMC article. Clinical Trial.
-
Pancreatic cancer.Annu Rev Pathol. 2008;3:157-88. doi: 10.1146/annurev.pathmechdis.3.121806.154305. Annu Rev Pathol. 2008. PMID: 18039136 Free PMC article. Review.
-
MUC16-mediated activation of mTOR and c-Myc reprograms pancreatic cancer metabolism.Oncotarget. 2015 Aug 7;6(22):19118-31. doi: 10.18632/oncotarget.4078. Oncotarget. 2015. PMID: 26046375 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous